The ZEST clinical trial, designed to evaluate niraparib (Zejula) for the prevention of breast cancer recurrence in patients with circulating tumor DNA (ctDNA), failed to accrue enough patients ...

A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR ...

SAN ANTONIO -- Endocrine therapy after breast-conserving surgery was associated with worse health-related quality of life ...

The Dragons' Den star's podcast is increasingly focused on bizarre medical advice that could lead to ill health in those who ...

The Institute for Clinical and Economic Review flagged five drugs whose prices were raised in 2023 with no evidence to ...

Two days after the FDA revealed that it had halted enrollment in trials of respiratory syncytial virus (RSV) vaccines that ...

Palbociclib plus ET improved outcomes over chemotherapy ± ET maintenance in patients with high-risk, HR+, HER2- metastatic breast cancer.

Explore Baker Brothers' biotech-focused 13F portfolio, with notable stake increases in Incyte, Summit Therapeutics, and other ...

While other big pharmas have faltered, Lilly made headway in a Phase 3 trial that could provide a treatment option to replace ...

Based on the results of this study, current recommendations suggest that TNBC patients with tumors larger than 2 cm or with ...

Some antibody-drug conjugates may cause such significant ocular toxicity that patients have vision damage or have to stop ...